If you have been reading about DAC linker and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2025-08-16. Where a claim depends on a specific study, the study is described rather than over-claimed.
The peptide backbone includes a D-alanine at position two, which resists cleavage by dipeptidyl peptidase IV, and several other substitutions that reduce degradation. Its molecular weight is roughly 3.4 kDa without the linker and about 3.6 kDa with it. The molecule is water soluble and is normally supplied as a lyophilized powder. Precise sequence and mass values depend on which variant is described, so technical documents usually state the exact form being referenced.
CJC-1295 is a synthetic peptide designed as a long-acting analogue of growth hormone-releasing hormone (GHRH). Its structure derives from the first 29 amino acids of native GHRH, a fragment often called GRF(1-29). Four substitutions were introduced to slow enzymatic breakdown and extend activity relative to the natural sequence. The compound was developed by ConjuChem as part of a broader effort to improve the pharmacokinetic profile of peptide hormones. It is studied in laboratory and clinical research settings rather than appearing as a naturally occurring substance.
Two related forms circulate in technical discussion under the same family name. The original version carries a drug affinity complex (DAC) that binds covalently to serum albumin after administration, and this linkage substantially extends circulation time. A second form, frequently written as modified GRF(1-29) or CJC-1295 without DAC, lacks that linker and clears much faster. The naming is a frequent source of confusion because the shorthand CJC-1295 can refer to either form depending on the source. Reports sometimes fail to specify which variant was studied.
At the pituitary, the peptide binds the growth hormone-releasing hormone receptor on somatotroph cells. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone. Somatostatin and other hypothalamic signals modulate this response. Negative feedback from insulin-like growth factor 1 also influences output. The same regulatory architecture operates with the native hormone. Whether the synthetic analog alters feedback dynamics over repeated exposure remains an open question. Most published receptor work uses cell models rather than intact human systems.
CJC-1295 is a synthetic peptide belonging to the growth hormone-releasing hormone analog family. It comprises twenty-nine amino acid residues derived from the N-terminal region of natural GHRH. The molecule incorporates several non-natural substitutions that increase resistance to enzymatic degradation. These modifications extend its activity compared with the native hormone fragment. Researchers use it to study pituitary growth hormone secretion in laboratory and clinical settings. This compound is distinct from native GHRH in its stability profile.
Two principal forms appear in the literature and in research supply. One carries a drug affinity complex, a maleimide-based group that forms a covalent bond with circulating albumin. This linkage slows clearance and produces a long-lasting elevation of peptide levels. The other form lacks that group and is often labeled MOD GRF(1-29). It has a much shorter circulation time. Both variants retain the same core receptor-binding sequence. Reported half-lives differ substantially between the two.
| Property | Value | Notes |
|---|---|---|
| Molecular weight (no linker) | ~3.37 kDa | Calculated from peptide sequence |
| Molecular weight (with linker) | ~3.65 kDa | Includes albumin-binding moiety |
| Appearance | White to off-white powder | Typically lyophilized |
| Solubility | Soluble in water | Also dissolves in aqueous buffers |
| Common synonyms | Modified GRF(1-29), DAC:GRF | Usage varies by source |
Two related forms appear under the CJC-1295 name. The simpler analogue, commonly written as modified GRF(1-29), carries the four substitutions but no additional conjugation. The second form attaches a maleimidopropionic acid linker to a lysine residue, a modification frequently called the drug affinity complex. That linker reacts with the free thiol on serum albumin to form a covalent bond. Because albumin has a long residence time in blood, the conjugated peptide stays in circulation far longer than the unconjugated analogue.
Receptor level activity follows the canonical GHRH pathway. The peptide binds the GHRH receptor, a class B G protein coupled receptor on somatotroph cells of the anterior pituitary. Binding raises intracellular cyclic AMP, which promotes calcium entry and the release of growth hormone into the bloodstream. Because the molecule acts at the same receptor as the endogenous hormone, its effect is superimposed on the natural pulsatile rhythm rather than replacing it. Whether sustained receptor occupation leads to desensitization is not fully settled.
CJC-1295 belongs to a class of synthetic peptides modeled on growth hormone releasing hormone, a forty-four amino acid signal produced by the hypothalamus. The compound is built from the first twenty-nine residues of the natural sequence, with four substitutions introduced at positions 2, 8, 15 and 27. These changes were designed to slow enzymatic breakdown while preserving receptor activation. The result is a peptide that is shorter than native GHRH and considerably more resistant to ordinary clearance pathways in circulation.
The second form adds a maleimide-bearing linker to the lysine at the carboxyl end. This group reacts with cysteine-34 on circulating serum albumin, forming a covalent bond that keeps the peptide in the bloodstream for far longer. ConjuChem developed the molecule as a way to extend the action of a peptide without frequent administration. The albumin attachment is the defining structural feature of the drug affinity complex version. Whether continuous exposure produces effects distinct from shorter pulses remains an unresolved research question.
The drug affinity complex is a maleimidopropionic acid group attached to a lysine side chain. It reacts with the free thiol of cysteine-34 on circulating albumin, forming a covalent bond. This conjugation keeps the peptide in the bloodstream and shields it from rapid renal filtration and proteolysis. Reported circulation half-lives for the albumin-bound form fall in the range of roughly six to nine days in early human studies.
Binding to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and stimulates growth hormone synthesis and release. Because the peptide acts upstream of the pituitary, effects are mediated through endogenous growth hormone rather than direct receptor activation in peripheral tissues. Increases in insulin-like growth factor 1 are generally described as a downstream consequence. Most published human exposure data come from small early-stage studies, and the clinical significance of the pharmacokinetic profile remains incompletely characterized.
The distinguishing feature of the DAC form is a maleimide-containing group that reacts with the free thiol of cysteine-34 on human serum albumin. This reaction forms a covalent bond without enzymatic assistance, and it takes place after the peptide enters the bloodstream. Because albumin is abundant and long-lived, the attached peptide is carried through circulation far longer than an unmodified fragment would survive. The chemistry is a deliberate pharmacokinetic strategy rather than a change to receptor activity.
Enzymatic protection is a separate mechanism from plasma protein binding. The four substitutions in the backbone reduce recognition by dipeptidyl peptidase IV, which normally cleaves the natural hormone within minutes. Without the reactive group, this resistance still yields only a short window of activity, generally reported in the range of tens of minutes. With it, reported half-lives in early human work extended to several days. The size of that gap is the main practical distinction between the two materials.
Pathways are required for the maintenance of homeostasis within an organism and the flux of metabolites through a pathway is regulated depending on the needs of the cell and the availability of the substrate. The end product of a pathway may be used immediately, initiate another metabolic pathway or be stored for later use. The metabolism of a cell consists of an elaborate network of interconnected pathways that enable the synthesis and breakdown of molecules (anabolism and catabolism).
The total complement of proteins present at a time in a cell or cell type is known as its proteome, and the study of such large-scale data sets defines the field of proteomics, named by analogy to the related field of genomics. Key experimental techniques in proteomics include 2D electrophoresis, which allows the separation of many proteins, mass spectrometry, which allows rapid high-throughput identification of proteins and sequencing of peptides (most often after in-gel digestion), protein microarrays, which allow the detection of the relative levels of the various proteins present in a cell, and two-hybrid screening, which allows the systematic exploration of protein–protein interactions. The total complement of biologically possible such interactions is known as the interactome. A systematic attempt to determine the structures of proteins representing every possible fold is known as structural genomics.
Smithsonian Institution Press, Washington and London. Monteiro A. (ed.) (2007). The Cone Collector 1: 1-28. Nelson, Laura (24 June 2004). "One slip, and you're dead..." Nature. 429 (6994): 798–799. doi:10.1038/429798a. Peters H, O'Leary BC, Hawkins JP, Carpenter KE, Roberts CM (2013). "Conus: first comprehensive conservation red list assessment of a marine gastropod mollusc genus". PLOS ONE. 8 (12) e83353. Bibcode:2013PLoSO...883353P. doi:10.1371/journal.pone.0083353. PMC 3871662. PMID 24376693. Petuch EJ (1986). "New South American gastropods in the genera Conus (Conidae) and Latirus (Fasciolariidae)". Proceedings of the Biological Society of Washington. 99: 8–14. Petuch, E. J. 1987. New Caribbean molluscan faunas. [v] + 154 + A1-A4, 29 pls. Coastal Education & Research Foundation: Charlottesville, Virginia Petuch, E. J. 1988. Neogene history of tropical American mollusks. [vi] + 217, 39 pls. Coastal Education & Research Foundation: Charlottesville, Virginia Petuch EJ (1990). "A new molluscan faunule from the Caribbean coast of Panama". Nautilus. 104: 57–70. Petuch EJ (1992). "Molluscan discoveries from the tropical Western Atlantic region. Part II. New species of Conus from the Bahamas Platform, Central American and northern South American coasts, and the Lesser Antilles". La Conchiglia. 24 (265): 10–15. Petuch EJ (2000). "A review of the conid subgenus Purpuriconus da Motta, 1991, with the descriptions of two new Bahamian species". Ruthenica: Russian Malacological Journal. 10: 81–87. Petuch EJ (2004). Cenozoic Seas. Boca Raton: CRC Press.
A large-scale study was conducted in Mexico. The study compared 793,487 adults vaccinated with different vaccines with 4,792,338 unvaccinated adults between 24 December 2020, and 27 September 2021.The results were as follows:
Traditional soy sauces are made by mixing soybeans and grain with mold cultures such as Aspergillus oryzae and other related microorganisms and yeasts (the resulting mixture is called Koji in Japan; the term koji is used both for the mixture of soybeans, wheat, and mold as well as for the mold itself). Historically, the mixture was fermented naturally in large urns and under the sun, which was believed to contribute extra flavors. Today, the mixture is placed in a temperature- and humidity-controlled incubation chamber. Traditional soy sauces take months to make:
Sources: en.wikipedia.org
== Other methods == Hydrogen–deuterium exchange Mass spectrometry Protein sequencing Protein synthesis Proteomics Peptide mass fingerprinting Ligand binding assay Eastern blotting Metabolic labeling Heavy isotope labeling Radioactive isotope labeling
=== Periodontal regeneration === Reproduction or reconstitution of a lost or injured part to restore the architecture and function of the periodontium becomes the integral part of comprehensive periodontal therapy. Conventional open flap debridement falls short of regenerating tissues destroyed by the disease. Platelet derived growth factor along with bone morphogenetic proteins are among the most researched growth factors in periodontal regeneration. Platelet rich fibrin showed significant improvement in clinical periodontal parameter as well as in radiograph when compared with open flap debridement alone in a meta analysis. Several bone graft materials have been used in the treatment of infrabony defects. Demineralized freeze dried bone allograft (DFDBA) has been histologically proven to be the material of choice for regeneration. Platelet-rich fibrin has shown significant results comparable to DFDBA for periodontal regeneration. One of the most common aesthetic problem encountered in the field of periodontology is gingival recession, which is perceived by the patients as increase in length of teeth. Though connective tissue graft is a gold standard procedure, PRF can be used as an alternative procedure by keeping patient's comfort in mind.
The U.S. Department of Health and Human Services agency responsible for ensuring the safety and effectiveness of all drugs, biologics, vaccines, and medical devices, including those used in the diagnosis, treatment, and prevention of HIV infection, AIDS, and AIDS-related opportunistic infections. The FDA also works with the blood banking industry to safeguard the nation's blood supply. Internet address: https://www.fda.gov/. (NLM) Frequentist methods
=== Christian Science Monitor libel case === The Christian Science Monitor also published a story on 25 April 2003, stating that it had documentary evidence that he had received "more than ten million dollars" from the Iraqi government. On 20 June 2003, the Monitor reported that its own investigation had concluded that the documents were sophisticated forgeries. Galloway sued The Christian Science Monitor for libel. In March 2004, he accepted damages and a public apology from the Monitor.
Sources: en.wikipedia.org
=== Ravenholm === In 2007 or 2008, Valve gave the Junction Point project to Arkane Studios in Lyon, France. They developed it into a game with the working title Ravenholm, referred to by some sources as Episode Four. Players controlled Adrian Shephard from Opposing Force, working alongside Father Grigori, who had taken refuge in an abandoned psychiatric hospital. Grigori was experimenting with the effects of headcrab venom on himself, and would mutate through the story. The player would use the magnet gun and traps created by Grigori against enemies. Arkane also implemented a nail gun that could create paths to conduct electricity and set traps. Valve gave Arkane freedom to develop Ravenholm, as they had with Gearbox and Opposing Force, providing feedback and technical support. With approximately one year left of development, Valve canceled the project. The Arkane founder, Raphaël Colantonio, believed that Valve decided it would be too expensive. Laidlaw said Valve felt the premise was creatively constrained, and that Arkane, like Valve with Episode Three, had struggled to discover fun new game mechanics with the Half-Life 2 tools. Ravenholm was first shown publicly in a 2020 Noclip documentary. Noclip released an hour of gameplay footage in 2022.
Strigolactones (SLs) were originally discovered through studies of the germination of the parasitic weed Striga lutea. It was found that the germination of Striga species was stimulated by the presence of a compound exuded by the roots of its host plant. It was later shown that SLs that are exuded into the soil also promote the growth of symbiotic arbuscular mycorrhizal (AM) fungi. More recently, another role of SLs was identified in the inhibition of shoot branching. This discovery of the role of SLs in shoot branching led to a dramatic increase in the interest in these hormones, and it has since been shown that SLs play important roles in leaf senescence, phosphate starvation response, salt tolerance, and light signalling.
is a physical property and defined as the optical rotation α at a path length l of 1 dm, a concentration c of 10 g/L, a temperature T (usually 20 °C) and a light wavelength λ (usually sodium D line at 589.3 nm):
== Companies and organizations == Companies such as Google, Microsoft and Amazon Web Services have offered platforms for deploying pre-built AI agents. Several protocols have been proposed for standardizing inter-agent communication, such as Agent2Agent, Gibberlink, and others. In December 2025, Linux Foundation announced the formation of the Agentic AI Foundation (AAIF), with the goal of ensuring that agentic AI evolves transparently and collaboratively.
=== Breastfeeding === ACE inhibitors may be used with caution during breastfeeding due to evidence showing small amounts being present in breastmilk. Enalapril is most commonly prescribed and has the most data published. The medications are considered safe for the mother.
Sources: en.wikipedia.org
No. It is a synthetic analogue modeled on the first 29 residues of human GHRH. The substitutions and any linker are laboratory modifications rather than features of the endogenous peptide.
Early development used the albumin-binding form, and a shorter variant was later discussed under the same label. Because the two differ in half-life and handling, ambiguity arises whenever a source omits the variant designation.
The compound derives from that fragment but is not identical to it. The parent fragment lacks the stabilizing substitutions, so its degradation rate and duration of action differ noticeably.
It is a synthetic peptide modeled on growth hormone-releasing hormone. The molecule is used in research on pituitary growth hormone secretion. It differs from the natural hormone through several stabilizing substitutions.